Skip to main content

ENGLISH · EVIDENCE OVERVIEW

Melanotan II
evidence profile

Experimental cyclic melanocortin peptide. This is a concise English overview, not a full translation. Read the evidence boundaries and original sources below; the detailed study and risk discussion remains available in Thai.

What do Class, Grade and Risk mean?

Melanotan II: conceptual scientific illustration for Tissue / Repair Research
VISUAL GUIDE · Melanotan II

Tissue / Repair Research

Category-level conceptual illustration, not a map of this molecule's receptor targets. It is not a treatment outcome and does not establish efficacy or safety.

QUICK ANSWER · AEO / GEO

Melanotan II is distinct from afamelanotide and bremelanotide. TGA's 17 August 2026 advisory found inconsistent content in tested nasal products and states there are no authorised Melanotan II products in Australia. FDA lists serious case reports and impurity/immunogenicity concerns; these do not quantify causality or universal incidence.

01

ENTITY FACTS

What should readers identify first?

MOLECULEMelanotan II
PHARMACOLOGYExperimental cyclic melanocortin peptide
PRIMECORE CLASSC
EVIDENCE GRADEC
RESEARCH TOPICTissue / Repair Research
LAST REVIEWED2026-08-30

What remains unknown?

Insufficient data in the current dataset

What limits these conclusions?

English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty.

Read original excerpts (Thai / mixed language)
  • ประโยชน์ของยาที่ออกฤทธิ์ melanocortin ตัวอื่นไม่โอนไป Melanotan II; Grade C ไม่ใช่คำรับรอง cosmetic use

This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.

02

EVIDENCE BOUNDARY

What this overview does not establish

  • An evidence grade does not rank this molecule against another treatment.
  • A molecule name does not establish the identity, purity or regulatory status of a product.
  • Animal, cell or biomarker findings do not automatically establish human clinical benefit.
  • Approval in one country or indication does not transfer globally.

Where can I check the evidence?

Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.

  1. FDA · significant compounding safety risks; Melanotan II entry
  2. Pilot phase I · PMID 8637402
  3. TGA laboratory safety advisory · 17 August 2026
03

FAQ · ANSWER ENGINE

Frequently asked questions

What is Melanotan II?

Melanotan II is described pharmacologically as Experimental cyclic melanocortin peptide. Melanotan II is distinct from afamelanotide and bremelanotide. TGA's 17 August 2026 advisory found inconsistent content in tested nasal products and states there are no authorised Melanotan II products in Australia. FDA lists serious case reports and impurity/immunogenicity concerns; these do not quantify causality or universal incidence.

Does Melanotan II have strong evidence?

PrimeCoreBio records Evidence Grade C. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.

Is Melanotan II approved everywhere?

No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.

Medical Disclaimer

Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.

Contact PrimeCoreBio

Choose a contact channel

General information only · No sales or medical advice